Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303 in Adult Healthy Volunteers

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303 in Adult Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Povetacicept (Primary) ; Povetacicept (Primary)
  • Indications Sjogren's syndrome; Systemic lupus erythematosus
  • Focus Adverse reactions; First in man
  • Acronyms RUBY-1
  • Sponsors Alpine Immune Sciences

    • Most Recent Events

    • 15 Nov 2023 According to an Alpine Immune Sciences media release, data from this study were presented at the American College of Rheumatology Convergence 2023, November 10-15, 2023.
    • 03 Nov 2023 According to an Alpine Immune Sciences media release, the company presented safety, tolerability, pharmacokinetic, and pharmacodynamic data at the American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM), November 1-3, 2023 in Phoenix, Arizona.
    • 05 Sep 2023 According to Alpine Immune Sciences media release, safety, tolerability, pharmacokinetic, and pharmacodynamic data of this study will be presented at 148th Annual American Neurological Association (ANA) Meeting in Philadelphia, PA.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top